Skip to main content
main-content

06-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: SELECT-PsA-2

Philip Mease describes the findings from the SELECT-PsA-2 trial of upadacitinib in patients with psoriatic arthritis and an inadequate response to biologic DMARDs (6.18).

Read the transcript

Related content

05-06-2020 | EULAR 2020 | Conference coverage | News

Upadacitinib shows promise for PsA

05-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: SELECT-PsA-1

Telemedicine in rheumatology: COVID-19 and beyond

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Image Credits